AI cuts drug discovery from years to weeks, targeting a 10-15 year pipeline where 90% of candidates never reach market approval. Eli Lilly's tirzepatide franchise generated $36.5 billion in 2025 ...
Drug discovery has long been a slow, expensive process of trial and error, and for a small clinical-stage company, every wasted experiment is capital it can scarcely afford. That is the backdrop for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results